Open AccessAssociation among resistin, adenylate cyclase-associated protein 1 and high-density lipoprotein cholesterol in patients with colorectal cancer: a multi-marker approach, as a hallmark of innovative predictive, preventive, and personalized medicine
Author(s) -
M Mihajlović,
Ainić,
Miron Sopić,
Milica Miljković,
Aleksandra Stefanović,
Jelena Vekić,
Vesna SpasojevićKalimanovska,
Aleksandra Zeljković,
Bratislav Trifunović,
Zeljka Stjepanovic
Publication year - 2019
Publication title -
the epma journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.177
H-Index - 34
eISSN - 1878-5085
pISSN - 1878-5077
DOI - 10.1007/s13167-019-00178-x
Subject(s) - resistin , medicine , endocrinology , colorectal cancer , cholesterol , high density lipoprotein , cancer , adipokine , leptin , obesity
Elevated concentrations of resistin have been reported in colorectal cancer (CRC), but its interactions with adenylate cyclase-associated protein 1 (CAP-1) are largely unexplored. We investigated resistin plasma concentration, peripheral blood mononuclear cells (PBMCs) resistin messenger ribonucleic acid (mRNA), and CAP-1 mRNA levels in CRC patients, as well as the impact of resistin gene polymorphism rs1862513 on the examined markers. We also explored associations of resistin with high-density lipoprotein cholesterol (HDL-C) and predictive potential of our parameters for CRC.